Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of VG-3927 in Healthy Adults and Alzheimer's Disease
NCT06343636Phase 1Completed
- Sponsor
- Vigil Neuroscience
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of VG-3927 in Alzheimer's disease (AD) (3 arms), sponsored by Vigil Neuroscience. Primary endpoint: Adverse Events. Started Sep 2023; status: completed.
02
Drugs
VG-3927
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06343636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343636.